1. Home
  2. CNTX vs LOAN Comparison

CNTX vs LOAN Comparison

Compare CNTX & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • LOAN
  • Stock Information
  • Founded
  • CNTX 2015
  • LOAN 1989
  • Country
  • CNTX United States
  • LOAN United States
  • Employees
  • CNTX N/A
  • LOAN N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • LOAN Real Estate Investment Trusts
  • Sector
  • CNTX Health Care
  • LOAN Real Estate
  • Exchange
  • CNTX Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • CNTX 60.7M
  • LOAN 57.7M
  • IPO Year
  • CNTX 2021
  • LOAN 1999
  • Fundamental
  • Price
  • CNTX $0.84
  • LOAN $5.39
  • Analyst Decision
  • CNTX Strong Buy
  • LOAN
  • Analyst Count
  • CNTX 5
  • LOAN 0
  • Target Price
  • CNTX $6.50
  • LOAN N/A
  • AVG Volume (30 Days)
  • CNTX 257.9K
  • LOAN 34.1K
  • Earning Date
  • CNTX 05-07-2025
  • LOAN 04-29-2025
  • Dividend Yield
  • CNTX N/A
  • LOAN 8.63%
  • EPS Growth
  • CNTX N/A
  • LOAN 2.37
  • EPS
  • CNTX N/A
  • LOAN 0.49
  • Revenue
  • CNTX N/A
  • LOAN $7,351,609.00
  • Revenue This Year
  • CNTX N/A
  • LOAN N/A
  • Revenue Next Year
  • CNTX N/A
  • LOAN $2.18
  • P/E Ratio
  • CNTX N/A
  • LOAN $10.90
  • Revenue Growth
  • CNTX N/A
  • LOAN 1.12
  • 52 Week Low
  • CNTX $0.55
  • LOAN $4.74
  • 52 Week High
  • CNTX $2.75
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 56.99
  • LOAN 48.35
  • Support Level
  • CNTX $0.80
  • LOAN $4.83
  • Resistance Level
  • CNTX $0.89
  • LOAN $5.38
  • Average True Range (ATR)
  • CNTX 0.11
  • LOAN 0.25
  • MACD
  • CNTX 0.03
  • LOAN -0.02
  • Stochastic Oscillator
  • CNTX 73.80
  • LOAN 49.62

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: